| Product NDC: | 75935-001 |
| Proprietary Name: | LAVIV |
| Non Proprietary Name: | azficel-T |
| Active Ingredient(s): | 15000000 1/mL & nbsp; azficel-T |
| Administration Route(s): | INTRADERMAL |
| Dosage Form(s): | INJECTION, SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 75935-001 |
| Labeler Name: | Fibrocell Technologies, Inc. |
| Product Type: | CELLULAR THERAPY |
| FDA Application Number: | BLA125348 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20110715 |
| Package NDC: | 75935-001-01 |
| Package Description: | 2 VIAL in 1 PACKAGE (75935-001-01) > 1 mL in 1 VIAL (75935-001-02) |
| NDC Code | 75935-001-01 |
| Proprietary Name | LAVIV |
| Package Description | 2 VIAL in 1 PACKAGE (75935-001-01) > 1 mL in 1 VIAL (75935-001-02) |
| Product NDC | 75935-001 |
| Product Type Name | CELLULAR THERAPY |
| Non Proprietary Name | azficel-T |
| Dosage Form Name | INJECTION, SUSPENSION |
| Route Name | INTRADERMAL |
| Start Marketing Date | 20110715 |
| Marketing Category Name | BLA |
| Labeler Name | Fibrocell Technologies, Inc. |
| Substance Name | AZFICEL-T |
| Strength Number | 15000000 |
| Strength Unit | 1/mL |
| Pharmaceutical Classes | Autologous Cultured Cell [EPC],Cells, Cultured, Autologous [Chemical/Ingredient],Fibroblasts [Chemical/Ingredient] |